MeSH tree: E04.950.774.435
An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for innovative imaging research that may help physicians identify patients at increased risk of chronic kidney disease ...
Jun 9, 2026
0
4
Today, small kidney tumors are most often treated with a minor operation in which all or part of the kidney is removed. However, in many cases, these small tumors can be treated with targeted cryotherapy, which destroys the ...
Mar 5, 2026
0
7
Major complications occur in 7.0% of patients undergoing nephrectomy with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), according to a study published online Dec. 17 in Urology Practice.
Dec 23, 2025
0
10
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form ...
Oct 3, 2024
0
53
For the first time in fifty years, results from a Phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Apr 17, 2024
0
48
While kidney cancer is rare in children, Wilms tumor is the most common type found in kids, with between 500 and 600 children diagnosed annually in the U.S. The disease most often affects kids ages 3 to 4.
Apr 8, 2024
0
32
For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Jan 27, 2024
0
61
UC Davis Comprehensive Cancer Center has taken part in testing the anti-cancer drug everolimus as part of a phase III clinical trial to see if it helped people with kidney cancer. Results from the clinical trial showed that ...
Jul 31, 2023
0
60
Based on findings from a study published today in The Lancet Regional Health—Americas, researchers at Johns Hopkins Medicine and three collaborating medical institutions suggest that people living with the human immunodeficiency ...
Jul 24, 2023
0
80
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
57
